{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:34:40Z","timestamp":1768340080475,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.bbr.2012.09.016","type":"journal-article","created":{"date-parts":[[2012,9,19]],"date-time":"2012-09-19T15:17:16Z","timestamp":1348067836000},"page":"86-95","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia"],"prefix":"10.1016","volume":"237","author":[{"given":"Gilda","family":"Neves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila B.","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andresa H.","family":"Betti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana A.","family":"Pranke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.M.","family":"Fraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliezer J.","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stela M.K.","family":"Rates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2012.09.016_bib0005","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1172\/JCI37335","article-title":"Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies","volume":"119","author":"Lewis","year":"2009","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.bbr.2012.09.016_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.04.011","article-title":"Schizophrenia, \u201cjust the facts\u201d. What we know in 2008. 2. Epidemilogy and etiology","volume":"102","author":"Tandon","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.bbr.2012.09.016_bib0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.tips.2008.03.009","article-title":"Antipsychotic drug action: antagonism, inverse agonism or partial agonism","volume":"29","author":"Strange","year":"2008","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.bbr.2012.09.016_bib0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/WNF.0b013e318215c2f7","article-title":"Neurobiological background for the development of new drugs in schizophrenia","volume":"34","author":"L\u00f3pez-Mu\u00f1oz","year":"2011","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.bbr.2012.09.016_bib0025","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.bbr.2012.09.016_bib0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4088\/PCC.v07n0602","article-title":"Atypicality of atypical antipsychotics","volume":"7","author":"Farah","year":"2005","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"key":"10.1016\/j.bbr.2012.09.016_bib0035","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives","volume":"11","author":"Newman-Tancredi","year":"2010","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1016\/j.bbr.2012.09.016_bib0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.bbr.2012.09.016_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2010.05.025","article-title":"\u201cJust the facts\u201d 5. Treatment and prevention past, present, and future","volume":"122","author":"Tandon","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.bbr.2012.09.016_bib0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pharmthera.2010.02.001","article-title":"The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature do clinical action","volume":"126","author":"Wong","year":"2010","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1016\/j.bbr.2012.09.016_bib0055","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuropharm.2008.05.025","article-title":"Serotonergic approaches in the development of novel antipsychotics","volume":"55","author":"Jones","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2012.09.016_bib0060","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1464-5491.2004.01199.x","article-title":"Schizophrenia, the metabolic syndrome and diabetes","volume":"21","author":"Holt","year":"2004","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.bbr.2012.09.016_bib0065","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug \u2013 pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1016\/j.bbr.2012.09.016_bib0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-244X-8-31","article-title":"Effectiveness of second generation antipsychotics: a systematic reviews of randomized trials","volume":"8","author":"Johnsen","year":"2008","journal-title":"BMC Psichiatry"},{"key":"10.1016\/j.bbr.2012.09.016_bib0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bbr.2012.09.016_bib0080","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1016\/S0968-0896(03)00487-5","article-title":"Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands","volume":"11","author":"Menegatti","year":"2003","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.bbr.2012.09.016_bib0085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1590\/S0100-879X2003000500010","article-title":"Dopaminergic profile of new heterocyclic N-phenylpiperazine derivatives","volume":"36","author":"Neves","year":"2003","journal-title":"Brazilian Journal of Medical and Biological Research"},{"key":"10.1016\/j.bbr.2012.09.016_bib0090","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.bmc.2010.01.040","article-title":"Searching for multi-target antipsychotics: discovery of orally active heterocyclic N-phenylpiperazine ligands of D2 and 5-HT1A receptors","volume":"18","author":"Neves","year":"2010","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.bbr.2012.09.016_bib0095","doi-asserted-by":"crossref","unstructured":"Gomes T, Pompeu T, Rodrigues D, Noel F, Menegatti R, Andrade C, et al. Biotransformation of LASSBio-579 and pharmacological evaluation of p-hydroxylated metabolite a N-phenylpiperazine antipsychotic lead compound. European Journal of Medicinal Chemistry; http:\/\/dx.doi.org\/10.1016\/j.ejmech.2012.08.011, in press.","DOI":"10.1016\/j.ejmech.2012.08.011"},{"key":"10.1016\/j.bbr.2012.09.016_bib0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pbb.2007.10.018","article-title":"Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiprazine antipsychotic prototypes LASSBio-579 and LASSBio-581","volume":"89","author":"Neves","year":"2008","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.bbr.2012.09.016_bib0105","unstructured":"Brasil. Congresso Nacional Lei n. 11.794. Regulamenta o inciso VII do \u00a7 1o do art. 225 da Constitui\u00e7\u00e3o Federal, estabelecendo procedimentos para o uso cient\u00edfico de animais; revoga a Lei no 6.638, de 8 de maio de 1979; e d\u00e1 outras provid\u00eancias. D.O.U., 2008."},{"key":"10.1016\/j.bbr.2012.09.016_bib0110","unstructured":"CIOMS. International Guiding Principles for Biomedical Research Involving Animals. Council for International Organizations of Medical Sciences; 1985."},{"key":"10.1016\/j.bbr.2012.09.016_bib0115","first-page":"170","article-title":"Hypnotic effect of ecdysterone isolated from Pfaffia glomerata (Spreng.) Pedersen","volume":"18","author":"Fenner","year":"2008","journal-title":"Brazilian Journal of Pharmacognosy"},{"key":"10.1016\/j.bbr.2012.09.016_bib0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1124\/jpet.109.151118","article-title":"Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4yl]-2,3-dihydro-1H-isoindol-1-one","volume":"330","author":"Satow","year":"2009","journal-title":"JPET"},{"key":"10.1016\/j.bbr.2012.09.016_bib0125","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1037\/0735-7044.102.5.748","article-title":"The catalepsy test: its ups and downs","volume":"102","author":"Sangberg","year":"1988","journal-title":"Behavioral Neuroscience"},{"key":"10.1016\/j.bbr.2012.09.016_bib0130","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2013the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.bbr.2012.09.016_bib0135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0014-2999(78)90251-0","article-title":"Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity","volume":"50","author":"Costall","year":"1978","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.bbr.2012.09.016_bib0140","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.pnpbp.2003.09.003","article-title":"Animal behavior models and the mechanisms underlying antipsychotic atypicality","volume":"27","author":"Geyer","year":"2003","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.bbr.2012.09.016_bib0145","series-title":"Textbook of psychopharmacology","article-title":"Animal models of depression and schizophrenia","author":"Weiss","year":"1998"},{"key":"10.1016\/j.bbr.2012.09.016_bib0150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0014-2999(78)90383-7","article-title":"Imipramine antagonism of apomorphine-induced hypothermia: a non-dopaminergic interaction","volume":"47","author":"Puech","year":"1978","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.bbr.2012.09.016_bib0155","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0006-8993(97)01229-8","article-title":"Independent roles of dopamine D1 and D2\/3 receptors in rat thermoregulation","volume":"781","author":"Salmi","year":"1998","journal-title":"Brain Research"},{"key":"10.1016\/j.bbr.2012.09.016_bib0160","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1124\/jpet.110.166710","article-title":"Behavioral indices in antipsychotic drug discovery","volume":"333","author":"Porsolt","year":"2010","journal-title":"JPET"},{"key":"10.1016\/j.bbr.2012.09.016_bib0165","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1196\/annals.1300.020","article-title":"Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia","volume":"1003","author":"Coyle","year":"2003","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.bbr.2012.09.016_bib0170","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.biopsych.2006.05.008","article-title":"Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder","volume":"59","author":"Powell","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.bbr.2012.09.016_bib0175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2012.09.016_bib0180","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.pnpbp.2004.08.003","article-title":"Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy","volume":"28","author":"Haleem","year":"2004","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatryis"},{"key":"10.1016\/j.bbr.2012.09.016_bib0185","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.pnpbp.2010.04.005","article-title":"Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders","volume":"34","author":"Shimizu","year":"2010","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatryis"},{"key":"10.1016\/j.bbr.2012.09.016_bib0190","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0014-2999(98)00536-6","article-title":"The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties","volume":"356","author":"Prinssen","year":"1998","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.bbr.2012.09.016_bib0195","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"A novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2012.09.016_bib0200","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.npp.1300940","article-title":"Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics havind D2 antagonist and 5-HT1A agonist properties","volume":"31","author":"Bardin","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2012.09.016_bib0205","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1017\/S1461145704005000","article-title":"Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia","volume":"8","author":"Newman-Tancredi","year":"2005","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2012.09.016_bib0210","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bbr.2009.05.015","article-title":"Differences among conventional, atypical and novel putative D2\/5-HT1A antipsychotics on catalepsyassociated behaviour in cynomolgus monkeys","volume":"203","author":"Auclair","year":"2009","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.bbr.2012.09.016_bib0215","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0022-3565(24)37732-8","volume":"286","author":"Millan","year":"1998","journal-title":"JPET"},{"key":"10.1016\/j.bbr.2012.09.016_bib0220","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1037\/0735-7044.102.4.544","article-title":"The role of mesolimbic dopamine in conditioned locomotion produced by amphetamine","volume":"102","author":"Gold","year":"1988","journal-title":"Behavioral Neuroscience"},{"key":"10.1016\/j.bbr.2012.09.016_bib0225","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0091-3057(00)00311-7","article-title":"Psychomotor-activating effects mediated by dopamine D2 and D3 receptor in the nucleus accumbens","volume":"67","author":"Canales","year":"2000","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.bbr.2012.09.016_bib0230","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0163-7258(01)00145-0","article-title":"Dopamine receptor functions: lessons from knockout mice","volume":"91","author":"Glickstein","year":"2001","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1016\/j.bbr.2012.09.016_bib0235","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0306-4522(02)00247-6","article-title":"Ventral striatal anatomy of locomotor activity induced by cocaine, d-amphetamine, dopamine and D1\/D2 agonists","volume":"113","author":"Ikemoto","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2012.09.016_bib0240","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-2999(84)90646-0","article-title":"A comparison of dopamine agonist actions to inhibit locomotor activity and to induce stereotyped behaviour in the mouse","volume":"105","author":"Bradbury","year":"1984","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.bbr.2012.09.016_bib0245","series-title":"Goodman & Gilman's the pharmacological basis of therapeutics","first-page":"417","article-title":"Pharmacotherapy of psychosis and mania","author":"Meyer","year":"2011"},{"key":"10.1016\/j.bbr.2012.09.016_bib0250","doi-asserted-by":"crossref","first-page":"PL275","DOI":"10.1016\/0024-3205(95)02151-8","article-title":"Is clozapine selective for the dopamine D4 receptor","volume":"57","author":"Durcan","year":"1995","journal-title":"Life Sciences"},{"key":"10.1016\/j.bbr.2012.09.016_bib0255","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0149-7634(03)00035-6","article-title":"Schizophrenia: from phenomenology to neurobiology","volume":"27","author":"Wong","year":"2003","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.bbr.2012.09.016_bib0260","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ddr.1208","article-title":"5-HT2C receptor antagonists: potential in schizophrenia","volume":"54","author":"Wood","year":"2001","journal-title":"Drug Development Research"},{"key":"10.1016\/j.bbr.2012.09.016_bib0265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-008-1433-z","article-title":"WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics","volume":"204","author":"Grauer","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2012.09.016_bib0270","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-011-2247-y","article-title":"Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties","volume":"216","author":"Newman-Tancredi","year":"2011","journal-title":"Psychopharmacology"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643281200602X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643281200602X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:47:47Z","timestamp":1744163267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016643281200602X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":54,"alternative-id":["S016643281200602X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2012.09.016","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}